Trial reportStroke2025
Medication Administration in Poststroke Dysphagia: Evaluating Swallowing Safety of Solid Dosage Forms.
Trial report in Stroke, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05173051 (Medication Intake of Solid Dosage Forms), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Medication Intake of Solid Dosage Forms: A Risk Factor for Patients With Stroke-induced Dysphagia?
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInternational guidelines recommend standardized dysphagia screening in acute stroke, as up to 75% of patients develop poststroke dysphagia. While medication swallowing is also advised for assessment, no validated screening tools or instrumental evidence exist on solid dosage form (SDF) management. Whole tablets are often crushed to reduce aspiration risk, yet the actual risk of aspiration for both forms remains unknown. Despite its widespread clinical use, crushed medication swallowing has never been evaluated using Fiberoptic Endoscopic Evaluation of Swallowing. Closing this evidence gap is essential for guiding safe medication administration in patients with dysphagic stroke.
methodsA prospective, single-center, cross-sectional study with an experimental design was conducted on 60 patients with acute stroke (<7 days). The swallowing safety and efficiency of 1 crushed placebo tablet and 3 different types of whole placebo tablets, each administered with an accompanying applesauce bolus, were compared using Fiberoptic Endoscopic Evaluation of Swallowing. The primary outcome was the incidence of unsafe swallowing, as determined by the Penetration-Aspiration Scale. Secondary outcomes included the presence and location of pharyngeal residue associated with each SDF condition.
resultsOf 60 patients with stroke (mean age, 73.4±10.7 years; 55% men) with a median Gugging Swallowing Screen score of 14 indicating moderate dysphagia, 58 patients completed the crushed SDFs trial. Whole SDFs were not swallowed (chewed, spit out, and stopped) in 20 of the 174 trials. All fully swallowed tablets (n=154) were safe, with no penetration or aspiration observed. In contrast, 22 of 154 accompanying boli (14.3%) and 7 of 58 crushed SDFs (12.1%) were rated unsafe, without a significant difference. Crushed SDFs caused significantly more vallecular residues (
conclusionsThese findings highlight the need to reconsider the routine practice of crushing SDFs for patients with dysphagic stroke. A paradigm shift towards using whole SDFs, guided by Fiberoptic Endoscopic Evaluation of Swallowing, could enable more frequent administration, reduce errors, and enhance medication efficacy. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05173051.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.